Kenneth Hoberman
Chief Operating Officer at STEMLINE THERAPEUTICS, INC.
Net worth: 4 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ronald Bentsur | M | 58 | 22 years | |
| Ivan Bergstein | M | 58 |
Lirum Therapeutics, Inc.
 Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 21 years |
| Michael Weiss | M | 58 | 31 years | |
| Shay Shemesh | M | 41 | 9 years | |
| Sean Power | M | 42 | 18 years | |
| Daniel Hume | M | 57 |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 9 years |
| Michael Carson | M | - | - | |
| Enrique Poradosu | M | 58 | 8 years | |
| Jeffrey Levitt | M | - | 6 years | |
| Sagar Lonial | M | 57 | 4 years | |
| Mark Sard | M | 59 |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 5 years |
| James Oliviero | M | 48 | 3 years | |
| Yann Echelard | M | 60 | 12 years | |
| Jenna A. Bosco | F | - | 13 years | |
| David Gionco | M | 63 | 10 years | |
| Laurence Charney | M | 76 | 12 years | |
| Matt Kaplan | M | 56 | 3 years | |
| Matt Hoberman | M | - |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 2 years |
| Adam Waldman | M | - | 6 years | |
| Nassir Habboubi | M | - | 3 years | |
| Peter McDonald | M | - |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Tarnok | M | 69 | 9 years | |
| Beth Levine | F | 60 | 1 years | |
| Mark Stier | M | 63 | 1 years | |
| Lindsay Rosenwald | M | 68 | 12 years | |
| Mark J. Schoenebaum | M | 51 | 7 years | |
| Jack Kaye | M | 80 | 10 years | |
| William James Kennedy | M | 79 | 9 years | |
| Neil Herskowitz | M | 67 | 11 years | |
| Ronald Renaud | M | 55 | 1 years | |
| Kevin Cameron | M | 64 | 11 years | |
| Eric Dobmeier | M | 55 | 6 years | |
| Joseph Feczko | M | 75 | 6 years | |
| Wyche Fowler | M | 83 | 10 years | |
| J. Buchi | M | 69 | 4 years | |
| Darren Cline | M | 59 | - | |
| Trishna Goswami | M | - | 1 years | |
| Robert Francomano | M | 58 | 5 years | |
| Jonathan Schwartz | M | 60 | 2 years | |
| Constance Ames | F | 38 | - | |
| Mark Jacobson | M | 40 | 5 years | |
| Owen O'Connor | M | - | 2 years | |
| Uri Ben-Or | M | 52 | - | |
| Hadas Reuveni | M | 56 | 3 years | |
| Eric Rose | M | 73 | - | |
| William Kane | M | 62 | - | |
| Eric Rowinsky | M | 67 | 5 years | |
| Kenneth Zuerblis | M | 64 | 8 years | |
| Alan Forman | M | 58 | 5 years | |
| I. Craig Henderson | M | 82 | 4 years | |
| Shane Lea | M | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 51 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Kenneth Hoberman
- Personal Network
